Puma Biotechnology, Inc. (PBYI)
-NYSE | Prev Close: | 38.55 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 36.00 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 11.00 - 39.34 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 142,943 |
|---|
| Market Cap: | 1.11B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -3.11 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- NYSE stocks posting largest percentage increasesAP(Thu, May 23)
- 5 Stocks Rising on Unusual Volumeat TheStreet(Mon, May 20)
- The Best- And Worst- Performing Biotech Stocks, May 10 To May 17at Forbes(Sun, May 19)
- Puma Biotech Gains After Rival Drug Data Show No Threatat Bloomberg(Fri, May 17)
- Puma Biotechnology declines to comment on stock moveat theflyonthewall.com(Fri, May 17)
- Puma Biotechnology Comment on Trading ActivityBusiness Wire(Fri, May 17)
- PUMA BIOTECHNOLOGY, INC. FinancialsEDGAR Online Financials(Wed, May 15)
- Puma Biotechnology to Present at UBS Global Healthcare ConferenceBusiness Wire(Tue, May 14)
- Puma Biotechnology Reports First Quarter 2013 Financial ResultsBusiness Wire(Thu, May 9)
- PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements andEDGAR Online(Thu, May 9)
- PUMA BIOTECHNOLOGY, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Thu, May 9)
- Puma Biotechnology to Present at Bank of America Merrill Lynch 2013 Health Care ConferenceBusiness Wire(Wed, May 8)
- Large Market Opportunity in Hepatitis C from a Volume Perspective: Brian Skorney Discusses Pockets in the Hepatitis C Space Where Companies Other Than Gilead (GILD) Will See ValueWall Street Transcript(Mon, Apr 29)
- Who Got Rich This Week: A Philosopher, A Biotech Businessman And Moreat Forbes(Sat, Apr 20)
- 3 Stocks Spiking on Big Volumeat TheStreet(Mon, Apr 15)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -2.44 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.62 |
|---|
| Mean Recommendation*: | 1.5 |
|---|
| PEG Ratio (5 yr expected): | 0.66 |
|---|
Business Summary
Puma Biotechnology, Inc., a development stage biopharmaceutical company, engages in the acquisition, development, and licensing of products for the treatment of various forms of cancer.
View More 
0.08%